S ubarachnoid hemorrhage (SAH)
is a life-threatening disease despite progress in diagnostics and treatment employing early neurosurgical intervention (1) . Early brain injury (EBI), which occurs within 48 hrs following cerebral aneurysm rupture, has been established as a factor for poor outcomes after SAH (2) . Thus, identifi ca- (2) . Thus, identifi ca-. Thus, identification of early neuroprotective strategies for possible clinical use is needed. Apoptosis is involved in the pathogenesis of EBI after experimental SAH (2) . Sphingosine 1 phosphate (S1P) is generated from sphingomyelin, an integral component of plasma membranes, by the sequential action of sphingomyelinase, ceramidase, and sphingosine kinase (SphK) (3) . Many factors can alter SphK activity and regulate subsequent S1P levels (3) . S1P regulates diverse biological processes including cell survival after binding to S1P receptor-1 to 5 (S1P1-S1P5) (4) .
Isoflurane is a volatile anesthetic and a lipophilic molecule (5) . It was reported that isoflurane activated SphK in renal tubule cells and induced renal protective effects (6) . We previously demonstrated that S1P1 activation was neuroprotective in cerebral ischemia via antiapoptosis (7) and that isoflurane reduced neonatal hypoxic-ischemic brain injury by a S1P1/ Akt pathway (8) . Therefore, activation of sphingomyelin metabolism by isoflurane can be a good candidate for neuroprotection against EBI after SAH.
In this study, we tested two hypotheses: 1) isoflurane posttreatment attenuates post-SAH EBI through antiapoptosis in mice, and 2) the antiapoptotic effect of isoflurane involves a sphingosine-related pathway including SphK expression and S1P receptor activation.
MATERIALS AND METHODS

Experimental Design and Animal Groups.
The animal and ethics review committee at Loma Linda University approved all protocols. One hundred seventy-nine 8-wk-old male CD-1 mice (30-38g; Charles River, Wilmington, MA) were used for the study.
To examine whether isoflurane attenuated EBI after SAH and had an antiapoptotic effect (designated as study 1), animals were randomly divided into three groups, and evaluated at either 24 or 72 hrs: sham-operat-ed130% O 2 170% medical air (O 2 -medical air; 24-hr and 72-hr sham groups, n  16 and 4, Objective: Isoflurane, a volatile anesthetic agent, has been recognized for its potential neuroprotective properties and has antiapoptotic effects. We examined whether isoflurane posttreatment is protective against early brain injury after subarachnoid hemorrhage and determined whether this effect needs sphingosine-related pathway activation.
Design: Controlled in vivo laboratory study. Setting: Animal research laboratory. Subjects: One hundred seventy-nine 8-wk-old male CD-1 mice weighing 30-38 g.
Interventions: Subarachnoid hemorrhage was induced in mice by endovascular perforation. Animals were randomly assigned to sham-operated, subarachnoid hemorrhage-vehicle, and subarachnoid hemorrhage12% isoflurane. Neurobehavioral function and brain edema were evaluated at 24 and 72 hrs. The expression of sphingosine kinase, phosphorylated Akt, and cleaved caspase-3 was determined by Western blotting and immunofluorescence. Neuronal cell death was examined by terminal deoxynucleotidyl transferase-mediated uridine 59-triphosphate-biotin nick end-labeling staining. effects of a sphingosine kinase inhibitor N, N-dimethylsphingosine or a sphingosine 1 phosphate receptor inhibitor VPC23019 on isoflurane's protective action against postsubarachnoid hemorrhage early brain injury were also examined.
Measurements and Main Results: Isoflurane significantly improved neurobehavioral function and brain edema at 24 hrs but not 72 hrs after subarachnoid hemorrhage. At 24 hrs, isoflurane attenuated neuronal cell death in the cortex, associated with an increase in sphingosine kinase 1 and phosphorylated Akt, and a decrease in cleaved caspase-3. The beneficial effects of isoflurane were abolished by N, N-dimethylsphingosine and VPC23019.
Conclusions: Isoflurane posttreatment delays the development of postsubarachnoid hemorrhage early brain injury through antiapoptotic mechanisms including sphingosine-related pathway activation, implying its use for anesthesia during acute aneurysm surgery or intervention. ( This study is partially supported by NIH NS060936 to Dr. Tang and NS053407 to Dr. Zhang.
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For information regarding this article, E-mail: johnzhang3910@yahoo. respectively), SAH1O 2 -medical air (24-hr and 72-hr vehicle groups, n  22 and 7, respectively), and SAH12% isoflurane1O 2 -medical air (24-hr and 72-hr treatment groups, n  21 and 10, respectively).
To determine whether this antiapoptotic effect involved SphK1 expression and S1P receptor activation (designated as study 2), we used a potent and specific SphK antagonist, N, N-dimethylsphingosine (DMS), and a S1P1and S1P3-receptor antagonist, VPC23019. VPC23019 competitively antagonizes S1P1 receptors ten-fold more potently than S1P3 receptors on neurons (9) . Animals were randomly divided into six groups and evaluated at 24 hrs post-SAH: dimethyl sulfoxide (DMSO; a vehicle)1sham-operated1O 2 -medical air (n  11), DMSO1SAH12% isoflurane1O 2 -medical air (n  15), DMS in DMSO1SAH12% isoflu-
Mouse SAH Model. SAH endovascular monofilament model was produced as described previously (10) . Briefly, animals were anesthetized with an intraperitoneal injection of ketamine/xylazine (100/10 mg/kg). A sharpened 4-0 monofilament nylon suture was advanced through the internal carotid artery to perforate the anterior cerebral artery. In the sham surgery, the filament was advanced 5 mm through the internal carotid artery without perforating the artery. Body temperature was kept constant (37.5  0.5°C) during the operation.
Drug Administration. One hour after SAH induction, 2% isoflurane (Baxter, Deerfield, IL) was continuously administered for 1 hour with 30% O 2 and 70% medical air.
DMS (Enzo, Plymouth Meeting, PA; final concentration, 0.17 µg/0.5 µL) and VPC23019 (Avanti, Alabaster, AL; final concentration, 0.26 µg/0.5 µL) were automatically infused at a rate of 0.1 µL/min intracerebroventricularly, 60 mins before the SAH induc tion (Supplemental Digital Content 1, http://links.lww.com/CCM/A417, which shows dose determination and preparation of drugs). The sham and vehicle groups were given the same volume (0.5 µL) of DMSO (1.1 g/mL/kg) diluted in phosphate-buffered saline.
Intracerebroventricular Infusion. Mice were placed in a head holder (Stoelting Stereotactic Instrument, Wood Dale, IL) and a 26s-gauge needle of a 10 µL Hamilton syringe (Microliter 701; Hamilton, Reno, NV) was inserted through a burr hole perforated on the skull into the right lateral ventricle using the following coordinates relative to bregma: 0.1 mm posterior, 0.9 mm lateral, and 3.1 mm below the horizontal plane of bregma (11) . The needle was removed 10 mins after completion of the infusion, and the burr hole was quickly plugged with bone wax.
Severity of SAH. The severity of SAH was blindly evaluated using the SAH grading scale at sacrifice (Supplemental Digital Content 1, http://links.lww.com/CCM/A417, which shows the SAH grading scale) (12) . Eight mice with SAH grading scores ≤7, which had no significant brain injury (10), were excluded.
Mortality and Neurological Scores. The neurological score was blindly evaluated at 24 and 72 hrs after SAH, based on the scoring system of Garcia et al (13) with modifications (Supplemental Digital Content 1, http://links.lww.com/CCM/A417, which shows neurological scoring). Mortality was calculated at 24 and 72 hrs after SAH.
Brain Water Content. Brains were quickly removed and separated into the left and right cerebral hemispheres, cerebellum, and brain stem, and weighed (wet weight) at 24 hrs (n  6 per group) and at 72 hrs (n  4 per group) after surgery. Next, brain specimens were dried in an oven at 105°C for 72 hrs and weighed again (dry weight). The percentage of brain water content (BWC) was calculated as ([wet weight-dry weight]/wet weight)  100% (10) .
Western Blotting. The left cerebral hemisphere (perforation side) at 24 hrs after SAH was used (n  5 per group). Western blotting was performed as previously described (7) Transferase-Mediated Uridine 5-Triphosphate-Biotin Nick End-Labeling Staining. Animals were euthanized 24 hrs after surgery, and brains were processed as previously described (10) . Tenmicron-thick coronal sections at the level of bregma 1 mm (caudally) were cut on a cryostat (LM3050S; Leica Microsystems, Bannockburn, IL). Double-fluorescence labeling was performed using the following primary antibodies: anti-SphK1 (1:250, Abgent, San Diego, CA), anti-phospho-Akt (Ser473) (1:100, Cell Signaling Technology, Danvers, MA), and anti-neuronal nuclei (1:200, Chemicon, Temecula, CA) antibodies, and then subjected to transferase-mediated uridine 5-triphosphate-biotin nick end-labeling (TUNEL) staining with an in situ cell death detection kit (Roche, Mannheim, Germany). TUNEL-positive cells were counted in three fields per case at 400 magnification and expressed as the mean number of TUNELpositive neurons/mm 2 with a fluorescence microscope (10) .
Statistics. Data were expressed as mean  SD. After confirming that each population being compared followed a normal distribution using Shapiro-Wilk W tests, statistical differences were analyzed using unpaired t tests or one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls method as appropriate. Differences in mortality were tested using Fisher's exact or chi-square tests as appropriate. p.05 was considered statistically significant.
In the statistical analysis, we calculated the power of the tests. The number of animals per group necessary to reach the desired power of 0.800 was in the range of 4-6.
RESULTS
Mortality and SAH Grade. In study 1, the mortality rate was not significantly different between the vehicle and treatment groups at 24 (20%, 4 of 20 mice vs. 20%, 4 of 20 mice) and 72 hrs (42.9%, 3 of 7 mice vs. 50%, 4 of 8 mice). No shamoperated mice died. There was no significant difference in SAH grade between the vehicle and treatment groups at 24 and 72 hrs (Fig. 1A) .
In study 2, no sham-operated mice died. The mortality rate was not significantly different among the DMSO1SAH12% isoflurane (26.7%, 4 of 15 mice), DMS in DMSO1SAH12% isoflurane (35.3%, 6 of 17 mice), VPC23019 in DMSO1SAH12% isoflurane (35.3%, 6 of 17 mice), DMS in DMSO1SAH (38.9%, 7 of 18 mice), and VPC23019 in DMSO1SAH (38.9%, 7 of 18 mice) groups at 24 hrs after SAH. SAH grade also did not show significant differences among the groups in study 2 at 24 hrs (Fig. 1B) .
Neurological Score and BWC. In study 1, although neurological score (Fig. 1C ; n  16) and BWC (ipsilateral hemisphere; Fig. 2A ; n  6) were significantly worse after SAH (p  .001, p  .001, respectively, ANOVA), a significant improvement was observed in the treatment group compared with the vehicle group at 24 hrs after SAH (p  .002, p  .001, respectively, ANOVA). However, isoflurane did not show beneficial effects at 72 hrs after SAH (p  .456, p  .224, respectively, ANOVA). In study 2, treatment with DMS and VPC23019 abolished isoflurane's protective effects on neurofunction at 24 hrs after SAH (p  .001, p  .001, respectively, ANOVA; Fig. 1D ). DMS but not VPC23019 also blocked isoflurane's beneficial effects on BWC (p  .035, p  .274, respectively, ANOVA; Fig. 2C ).
Effect of Isoflurane on Sphingosine-Related Antiapoptotic Pathway. Western blot analyses showed that SphK1 and phosphorylated Akt (p-Akt) were significantly increased in the treatment group compared with the sham (p  .020, p  .001, respectively) and vehicle groups (p  .017, p  .001, respectively, ANOVA). There was no significant difference in SphK2 expression among the groups at 24 hrs after SAH (Fig. 3, A-C) . Although cleaved caspase-3 was significantly increased in the vehicle group compared with the sham group (p  .001), isoflurane significantly reduced cleaved caspase-3 expression at 24 hrs after SAH (p  .019; Fig. 3D ).
Consistent with the Western blot results, immunofluorescence analyses revealed that TUNEL-positive neurons in the left basal cortex were seen more prominent in the vehicle group compared to the sham group (Fig. 4A) . A significant decrease in TUNEL-positive neurons was observed in the treatment group (p  .001, ANOVA; Fig. 4B ). The expression of SphK1 and p-Akt were more prominent in the treatment group than the vehicle group and were seen even in some TUNELpositive cells (Fig. 5A and 5B) .
In study 2, although isoflurane treatment significantly increased SphK1 expression and Akt phosphorylation compare to the sham group (p  .016, p  .007, respectively), both DMS (p  .001, p  .002, respectively) and VPC23019 (p  .006, p  .002, respectively) abolished this effect (ANOVA; Fig. 6A and 6B) . Further, isoflurane decreased cleaved caspase-3, which was reversed by DMS (p  .003, ANOVA; Fig. 6C ).
DISCUSSION
The present study showed that isoflurane posttreatment attenuated EBI at 24 hrs after SAH, and that the neuroprotective effect was associated with decreased neuronal apoptosis. This antiapoptotic effect needed at least partly sphingosine-related pathway activation including SphK1 and S1P1/3 receptors. However, the neuroprotective effects of isoflurane were not shown at 72 hrs after SAH.
Volatile anesthetics have been shown to be protective against ischemic injury in neural tissues when used as preconditioning (14, 15) . Among the volatile anesthetic agents, isoflurane is the most neuroprotective. The following different mechanisms underlying the beneficial effects of isoflurane have been proposed in diverse animal models of ischemic injuries: modulation of excitotoxicity (16), induction of inducible nitric oxide synthase (15) , modulation of mitochondrial K ATP channels (17) , and activation of S1P1 receptors and phosphatidylinositol-3 kinase pathways (6, 8, 18) . It was reported that isoflurane increased SphK activity and SphK1 mRNA expression in both in vivo murine model of renal ischemiareperfusion injury as well as an in vitro model (6) . In this study , 2% isoflurane administered for 1 hr after SAH improved neurological scores, decreased BWC, and increased SphK1 expression and Akt activation, which is a well-known principal factor in antiapoptotic signaling (7, 19) . Furthermore, isoflurane treatment decreased cleaved caspase-3 expression and neuronal cell death at 24 hrs after SAH in mice. These findings suggested that isoflurane posttreatment had a caspasedependent antiapoptotic effect, and that this antiapoptotic effect was mediated by SphK1 and Akt activation, which were induced by S1P1 or S1P3 receptor activation. In addition, this study showed that VPC23019 suppressed SphK1 upregulation, indicating that SphK1 was downstream of S1P1/3 receptors. Because S1P is generated from sphingosine by SphK and then activates S1P receptors (3), SphK1 may work through both upstream and downstream of S1P receptors in EBI after SAH.
It was reported that isoflurane did not prevent postischemic neuronal apoptosis or cerebral infarction, although isoflurane reduced early neuronal death and delayed the development of cerebral infarction caused by ischemia (16, 20, 21) . In this study, isoflurane also suppressed EBI at 24 hrs, but failed to prevent neuronal injuries at 72 hrs after SAH. Although S1P is upregulated by SphK activation, S1P is a short-lived lipid and susceptible to enzymes, such as sphingosine phosphate phosphatase-1 and S1P-lyase (22) . Furthermore, in the absence of stimulus to increase SphK1 expression, the balance of sphingolipid rheostat (3) is shifted to increasing sphingosine and ceramide, so that S1P decreases and no antiapoptotic effect occurs. This might explain why one-dose or short-duration isoflurane treatment at an acute stage did not have long-term neuroprotective effects. It would be interesting to see whether short-duration isoflurane treatment over multiple days could provide prolonged protection. And also, in a clinical setting, early surgery or intervention to obliterate ruptured cerebral aneurysm is the standard therapy for aneurysmal SAH and needs general anesthesia. Thus, this study suggests that isoflurane is useful as anesthetic agents during early aneurysm surgery or intervention to delay the development of EBI, although other strategies need to be developed to prevent neuronal injuries at later stages.
It is important that the optimal concentration of isoflurane is delivered when used for neuroprotection. In this study, we used 2% isoflurane treatment because it is clinically relevant (8, 18) . It has been reported that 1 minimum alveolar concentration (1.4%) isoflurane is required to anesthetize 50% subjects in CD-1 mice (23). On the other hand, 1% isoflurane caused spatial learning impairment and neurodegeneration by increasing apoptosis, whereas 1.5% or 2% isoflurane had no adverse effects in mice (24) . In cats, 3% isoflurane broke down the blood-brain barrier (25) . Isoflurane's neuroprotection may involve glutamate and/or -aminobutyric acid receptors (16) , but the effects may be harmful on the developing brain (26) or by excessive exposure of isoflurane (27) . Thus, further study is needed to find more effective dose and exposure time in the treatment of post-SAH brain injury. Another issue is whether isoflurane affects cerebral blood flow (CBF) after SAH. Recently, it was reported that 1.1%-2.1% isoflurane dosedependently increased CBF in rats (28) . Increased CBF potentially suppresses ischemic neuronal injuries. But, we can assume that isoflurane has no or very little effect on changing the CBF given the sustained increase in intracranial pressure (29) , which persists in endovascular perforation model that mimics clinical mechanism of artery rupture. However, effects of isoflurane on CBF in post-SAH brain remain undetermined.
This study failed to show isoflurane's neuroprotective effects in terms of neurological scores and BWC at 72 hrs post-SAH. However, we cannot exclude the possibility that these two tests could not detect isoflurane's neuroprotective effects at 72 hrs. More importantly, isoflurane treatment was conducted only once and we do not know if multiple treatments at different time courses will be effective. To address this issue, it will be worthwhile to perform other more detailed neurobehavioral tests at later stages with more than one treatment. In addition, isoflurane may have other protective effects that were not evaluated in this study. For example, immunofluorescence used in this study prevented us from assessing morphologically intact neurons and necrotic cell loss, which are potentially affected by isoflurane (30, 31) . Also, isofl urane may suppress activa-. Also, isoflurane may suppress activation of microglia or astroglia, leading to less gliosis. These studies are beyond the scope of this project and therefore warrant further investigation.
In conclusion, this study demonstrated that isoflurane posttreatment has an antiapoptotic effect on neurons at least for 24 hrs post-SAH, and that this effect involves the sphingosine-related pathway. The identification of anesthetics with properties that help to delay or attenuate neuronal damage as a consequence of aneurysmal rupture is clinically highly relevant, and this study suggested that isoflurane is a good candidate for it. This is because the first step for intensive care of aneurysmal SAH patients is aneurysmal obliteration under general anesthesia. Further studies are warranted to elaborate the dose and duration of isoflurane treatment and to test the combination with other neuroprotectants for EBI after SAH. 
